Lisa Belter

Lisa Belter

Auto-generated profile, based on publicly available information

Lisa Belter

Cure SMA, Elk Grove Village, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LBLisa Belter
Lisa Belter
RCRosángel Cruz
Rosángel Cruz
JJJill Jarecki
Jill Jarecki
Background: Individuals and/or caregivers of individuals affected by spinal muscular atrophy (SMA) completed the 2019 Cure SMA Community Update Survey, online, assessing health-related quality of life (HRQoL), loss of work productivity, and fatigue using the Health Utilities Index Questionnaire (HUI), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue SF), respectively. The purpose was to collect baseline quality of life results among individuals affected by SMA using the above Patient Reported Outcome Measures (PROMs). Results: Of 666 surveys completed between March and May 2019, 478 were included in this analysis, accounting for duplicates, missing data, or deaths. The breakdown across SMA type I, II and III was 25, 47 and 28%, respectively. Responses were characterized by current functional status/milestone, with subsets for “permanent ventilation,” “non-sitters,” “sitters,” “walk with support,” and “walk alone.” WPAI and HUI respondents included affected adults and caregivers. The PROMIS Fatigue SF was completed by the primary caregiver of affected children. Overall, those affected by a less severe form of SMA and with a higher functional status reported higher HRQoL and lower work productivity and activity impairment. All affected individuals reported higher fatigue levels than the general population. Conclusions: This study offers useful insights into the burden of SMA among affected individuals and their caregivers. The results provide a baseline picture of the patient and caregiver experience with SMA in a post-treatment era from which to measure year-over-year changes in quality of life scores from new therapies and improved care. The WPAI demonstrates the significant impact of work productivity among SMA populations. Aspects of the HUI seem more appropriate to certain SMA sub-populations than others. Measures from the PROMIS Fatigue SF appear to under-represent the burden of fatigue often reported by SMA individuals and caregivers; this may, perhaps be due to a lack of sensitivity in the questions associated with fatigue in the SMA affected population, when compared with other studies on this topic. Overall, these results suggest the need for SMA-specific quality of life outcome measures to fully capture clinically meaningful change in the SMA population.

1 September 2024 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
LBLisa Belter
Lisa Belter
JTJennifer L. Taylor
Jennifer L. Taylor
EJErica Jorgensen
Erica Jorgensen
JGJacqueline Glascock
Jacqueline Glascock
SWSarah M. Whitmire
Sarah M. Whitmire
MSMary Schroth
Mary Schroth
Spinal muscular atrophy (SMA) is an autosomal recessive disease resulting in progressive motor neuron death, muscle denervation, and weakness.1 Rapid, widespread implementation of newborn screening (NBS) for SMA in the US since 2018 has facilitated the collection of precise SMA data, including birth prevalence.2 Cure SMA, a US-based patient advocacy organization supporting people with SMA, partnered with state public health laboratories (PHLs) to collect data on infants who were screened for SMA and confirmed to have SMA diagnosis. This study estimated the birth prevalence of SMA and evaluated the distribution of SMN2 copy number in US newborns with SMA.

Verified
Journal Article
Open access
LBLisa Belter
Lisa Belter
RCRosángel Cruz
Rosángel Cruz
SKSierra Kulas
Sierra Kulas
EMEmily McGinnis
Emily McGinnis
ODOmar Dabbous
Omar Dabbous
JJJill Jarecki
Jill Jarecki
Background: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease.

13 October 2020 in Journal of Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
LBLisa Belter
Lisa Belter
JJJill Jarecki
Jill Jarecki
SRSandra P. Reyna
Sandra P. Reyna
RCRosangel Cruz
Rosangel Cruz
CJCynthia C. Jones
Cynthia C. Jones
APAngela D. Paradis
Angela D. Paradis
Background: Cure SMA maintains the largest patient-reported database for people affected with spinal muscular atrophy (SMA). In 2017, Cure SMA initiated annual surveys with their membership to collect demographic and disease characteristics, healthcare, and burden of disease information from patients and caregivers. Objective: To summarize results from two large-scale Cure SMA surveys in 2017 and 2018. Methods: Cure SMA database members were invited to complete surveys; these were completed by caregivers for living or deceased individuals with SMA and/or affected adults. Results: In 2017, 726 surveys were completed for 695 individuals with SMA; in 2018, 796 surveys were completed for 760 individuals with SMA. Data from both survey years are available for 313 affected individuals. Age at symptom onset, distribution of SMN2 gene copy number, and representation of each SMA type in the surveys were consistent with that expected in the SMA population. In the 2018 survey, the average age at diagnosis was 5.2 months for SMA type I and the reported mean age at death for this subgroup was 27.8 months. Between survey years, there was consistency in responses for factors that should not change within individuals over time (e.g., reported age at diagnosis). Conclusions: Results from the Cure SMA surveys advance the understanding of SMA and facilitate advocacy efforts and healthcare services planning. Longitudinal surveys are important for evaluating the impact of effective treatments on changing phenotypes, and burden of disease and care in individuals with SMA.

19 October 2023 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
LBLisa Belter
Lisa Belter
IPIlse Peterson
Ilse Peterson
JJJill Jarecki
Jill Jarecki
Introduction Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive muscle weakness and atrophy. While chronic fatigue is a common manifestation of SMA, the field lacks comprehensive data to assess the extent of its impact. Cure SMA, an SMA patient advocacy organization, conducted an online survey of its adults with SMA community members to measure the impact of fatigue. Methods All survey respondents were asked to complete questions on demographics, use of SMA treatment, and quality of life, but respondents were randomized to receive three of the following fatigue instruments: the Modified Fatigue Impact Scale (MFIS), Multidimensional Fatigue Inventory (MFI), Fatigue Severity Scale (FSS), PedsQL™ Multidimensional Fatigue (PedsQL MF) Scale, and Spinal Muscular Atrophy Health Index (SMA-HI) fatigue modules. Scales were evaluated for reliability and overall fatigue scores were evaluated by multivariate regression models to determine which variables were related to the final scores of each instrument. Results A total of 253 adults completed the online survey. When measured against the general population, statistically significant differences were found among adults with SMA for certain variables within each measurement instrument. However, there did not appear to be differences in fatigue levels among key subgroups within the SMA population. Conclusions This was the first use of more than two fatigue questionnaires simultaneously in SMA. The lack of a consistent relationship between SMA severity and fatigue levels was surprising. This may be related to the lack of specificity of the instruments for this population. An SMA-specific scale is needed to evaluate differences in fatigue impact across the SMA population.

7 February 2024 in Telemedicine and e-Health
Verified
Journal Article
Open access
IPIlse S. Peterson
Ilse S. Peterson
LBLisa T. Belter
Lisa T. Belter
MCMary A. Curry
Mary A. Curry
JJJill Jarecki
Jill Jarecki
Background:Telemedicine may increase access to clinical care, particularly for mobility-limited communities such as the spinal muscular atrophy (SMA) community. However, much of the information on exposure to and attitudes toward telemedicine in neuromuscular diseases generally and SMA specifically is anecdotal or from focus groups. Gaining greater insight into patient perspectives is important, given telemedicine's potential for expanding access to care and growing use of telemedicine as a result of technology advances and the COVID-19 pandemic. Methods:Cure SMA collected information on the SMA community's exposure to, comfort with, and perceived effectiveness of telemedicine through its 2021 Community Update Survey. The final analytic sample represented 463 SMA-affected individuals, resident in the United States. Descriptive analyses, correlations, and ordered logit regression models were used to characterize the sample and identify predictors of exposure, comfort, and perceived effectiveness. Data were analyzed on weighted and unweighted bases to account for differences between the survey sample and the SMA community. Stratified analyses were used to compare self-completed surveys with caregiver-completed surveys. Results:463 individuals answered questions about telemedicine. Approximately four-fifths of these respondents had used telemedicine previously. Factors predicting greater likelihood of prior telemedicine use included male gender, increasing income, having received drug treatment for SMA, history of mental illness, and having non-neutral views regarding comfort and perceived effectiveness of telemedicine. Several factors were also significant predictors of comfort with and perceived effectiveness of telemedicine. Stratified analyses indicated differences between self-completed and caregiver-completed surveys. Conclusion:These results can provide insight into patient experiences with telemedicine and can inform approaches to its use by health care professionals and clinical trial sponsors.